Google
Trusted Resources: News & Events
Latest announcements and gatherings
Alzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell Disease
Memantine, a standard treatment for Alzheimer’s disease, has shown promise in treating sickle cell disease (SCD) in six patients, a 12-month pilot clinical trial found. The findings were presented at the American Physiological Society’s Physiological and Pathophysiological Consequences of Sickle Cell Disease conference in Washington, D.C.
The study’s lead researcher, Anna Bogdanova PhD, presented the paper, titled “Treatment of the First Sickle Cell Disease Patients with Antagonist of N-Methyl D-Aspartate Receptor Memantine: Biological Outcome of the MemSID Trial.” Calcium levels in the red blood cells (RBCs) of people with SCD are often excessive. The team of Swiss researchers reasoned that inhibiting a kind of receptor on the cells, known as an NMDA receptor, which when activated allows calcium to enter cells, might reduce the damage potentially caused by calcium in the red blood cells of SCD patients.
+myBinderRelated Content
-
Fever management practices among sickle cell disease programs in low and middle-income countriesUnder-5 mortality for children with sick...
-
Treatment options for sickle cell disease – chronic blood transfusionsBlood transfusions are scheduled and giv...
-
CRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
-
Chief Patient Officer SummitJuly 18-20 | Boston, Massachusetts This...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
Public Meeting on Patient-Focused Drug Development for Chronic PainMeeting Information: On July 9, 2018, F...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.